Cagrilintide/semaglutide
REDEFINE
Novo Nordisk · Phase 3 · Not yet recruiting · Enrollment 1408
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| CagriSema | n/r | n/r | n/r | n/r |
| Semaglutide | n/r | n/r | n/r | n/r |
| Cagrilintide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- CagriSema: endpoint not reported
- Semaglutide: endpoint not reported
- Cagrilintide: endpoint not reported
- Placebo: endpoint not reported